RECURSION PHARMACEUTICALS, INC. — Form 8-K filed 2026-10-15

Filing text preview

Recursion signed an underwriting agreement on October 15, 2026 to sell 61,540,000 Class A shares at $3.25, expecting about $200 million in gross proceeds, with closing expected October 16 and 45-day lock-ups for executives and directors. Estimated cash, cash equivalents and restricted cash at September 30, 2026 was about $561 million, including roughly $86 million of net ATM proceeds, funding operations into 2029. Sanofi optioned the first development candidate, triggering a $10 million milestone and bringing collaboration payments to $144 million. REC-4881 showed a 47% median polyp burden reduction in FAP; REC-1245's 45 mg dose was selected for expansion.